Abstract. Effects of small iv doses of 1.25-dihydroxy\x=req-\ and 24.25-dihydroxy-vitamin D3 (1 \g=m\g) were studied in 10 normal subjects. Injection of 1.25 (OH)2D3 was associated with small but significant increases in plasma calcium and phosphate but plasma levels of immunoreactive parathyroid hormone (iPTH) 
Physiological doses of this metabolite (less than 1 (xg/day) increase the intestinal absorption of cal¬ cium and phosphorus and promote the remineralisation of bone in dietary deficiency of vitamin D and in osteomalacia due to several causes (Deluca & Schnoes 1976; Norman & Henry 1974) . A further metabolite of vitamin D is 24.25-dihydroxyvitamin D3 (24.25(OH)2D3), the daily producdon of which is quantitatively similar to that of 1.25(OH)2D3 (Mawer et al. 1975) . The (Canterbury et al. 1978; Care et al. 1977; Chertowetal. 1975) .
The role of these metabolites in the control of the secretion of PTH and CT has not been ade¬ quately documented in physiological situations in man. For that reason, we decided to study the acute effects of the iv injection of both 1.25(OH)2D3 and also studied the urinary excretion rate of both adrenaline and noradrenaline following these in¬ fusions. Plasma and urine concentrations of calcium (Gitelman 1967 ), phosphorus (Hurst 1964; Kraml 1966) was less than 10% for concentrations of iPTH between 1 and 9 mIU/ml ).
Patients and Methods

Patients
Plasma levels of immunoreactive calcitonin (iCT) were measured by a radioimmunoassay using techniques pre¬ viously descried (Heynen & Franchimont 1974 ing plasma iPTH and iCT levels within a period of 2 h in normal subjects (Franchimont & Heynen 1976 (Tanaka et al. 1979; Golden et al. 1979 ). Large doses of 24.25(OH)2D3 in rat have been reported to decrease plasma iPTH (Nko et al. 1981 
